1386
W. P. Nawrocka et al.
3-Amino-2-(4 ꢀ-nitrophenacylthio)-4(3H)-quinazolinone (13)
Yield: 72%; white solid; m.p. 207–209◦C. IR (KBr): ν [cm−1] = 3460,
3360 (NH), 3080 (CH), 2900 (CH2), 1685, 1660 (C O), 1620 (NH), 1490
1
(C N), 1440 (CH2), 1545, 1340, 840 (NO2), 760, 740 (CH arom.). H
NMR (DMSO-d6): δ = 5.23 (s, 2H), 6.63 (s, 2H), 6.64 (m, 1H), 6.87 (d,
J = 8.4 Hz, 1H), 7.25 (m, 1H), 7.56 (d, J = 7.8 Hz, 1H), 8.34 (m, 4H).
MS (70 eV): m/e [%] = 358 (5), 357 (13), 356 (76), 206 (5), 160 (13), 150
(21), 121 (11), 120 (100), 118 (73), 104 (16), 92 (33), 91 (4), 65 (17), 39
(3).
REFERENCES
[1] The Merck Index. An Encyclopedia of Chemical Drugs and Biologicals., (Merck and
Co. Inc., Rathway, NY, 1989), 11th ed.
[2] (a) P. R. Marsham, L. R. Hughes, A. L. Jackman, and D. L. Alison, J. Med. Chem., 34,
1594 (1991); (b) H. H. Backus, H. M. Pinedo, D. Wouters, C. M. Kuiper, G. Jansen,
C. J. Groeningen, and G. J. Peters, Oncology Research, 12, 231 (2000); (c) T. S. Mok,
T. W. Leung, S. D. Lee, Y. Chao, A. T. Chan, A. Huang, M. Lui, K. Chak, A. Johnston,
and P. Johnson, Cancer Chemotheraphy and Pharmacology, 44, 307 (1999); (d) S. E.
Weber, T. M. Bleckman, J. Attard, J. G. Deal, V. Kathardekar, and K. M. Welsh, J.
Med. Chem., 36, 733 (1993).
[3] (a) G. J. Wang, J. Shan, P. K. Pang, M. C. Yang, C. J. Chou, and C. F. Chen, J.
Pharmacol. Exp. Ther., 276, 1016 (1996); (b) J. R. Sheu, W. C. Hung, Y. M. Lee, and
M. H. Yen, Eur. J. Pharmacol., 318, 469 (1996); (c) H. Matsuda, J. X. Wu, M. Linuma,
and M. Kobo, Biol. Pharm. Bull., 20, 243 (1997); (d) S. B. Mhaske and N. P. Argade,
Tetrahedron, 62, 9787 (2006).
[4] H. Amin, D. R. Mehta and S. S. Samarth, Arzneim. Forsch., 14, 218 (1970).
[5] W. Nawrocka and J. J. Stas´ko, Bull. Chim. Farm., 137, 35 (1998).
[6] W. Nawrocka and J. J. Stas´ko, Bull. Chim. Farm., 140, 195 (2001).
[7] W. Nawrocka and J. J. Stas´ko, Bull. Chim. Farm., 141, 84, (2002).
[8] W. Nawrocka and J. J. Stas´ko, Farm. Pol., 60, 603 (2004).
[9] W. Nawrocka and B. Sztuba, Polish J. Chem., 70, 197 (1996).
[10] W. Nawrocka and J. J. Stas´ko, Polish J. Chem., 71, 792 (1997).
[11] W. Nawrocka and M. Zimecki, Arch. Pharm. Pharm. Med. Chem., 330, 339 (1997).
[12] (a) A. Yesilada, E. Zorlu, F. Aksu, and E. Yesilada, Farmaco, 51, 595 (1996); (b) M.
Sugiura, Y. Naito, Y. Yamaura, C. Fukaya, and K. Yokoyama, Chem. Pharm. Bull.,
37, 1039 (1989); (c) S. Iwakami, M. Shibuya, C. Tseng, F. Hanaoka, and U. Sankawa,
Chem. Pharm. Bull., 34, 3960 (1986).
[13] E. M. Schneidewind, A. Buge, H. Kala, J. Metzner, and A. Zschunke, Pharmazie, 34,
103 (1979).
[14] (a) A. Varnavas, C. Nisi, L. Lassiani, G. Sava, L. Perissin, and E. Boccu, Arzneim.
Forsch. Drug. Res., 41, 1168 (1991); (b) L. Liu, W. R. Hudgins, S. Shack, M. Q. Yin,
and D. Samid, Int. J. Cancer, 62, 345 (1995).
[15] G. Blazso, M. Hilbert, P. Hegyes, A. Megyeri, and M. Gabor, Pharmazie, 53, 425
(1998).
[16] W. Nawrocka, H. Liszkiewicz, A. Nawojski, M. Wilimowski, L. KÍdzierska-Goüdzik,
J. BarczyÒska, W. Wojewo´dzki, E. Duú, A. Szelg, and M. Rutkowska, Pol. J. Phar-
macol. Pharm., 43, 495 (1991).